We recently published a list of Insiders Are Spending Big: 15 Stocks Leading in March. In this article, we are going to take a look at where Mineralys Therapeutics, Inc. (NASDAQ:MLYS) stands against other stocks that are receiving the most insider investment in March.
“The economy is strong overall and has made significant progress toward our goals over the past two years,” Federal Reserve Chair Jerome Powell said during a press conference Wednesday following the decision announcement. “Labor market conditions are solid, and inflation has moved closer to our 2% longer-run goal, though it remains somewhat elevated.”
The Fed announced on Wednesday that it would maintain the federal funds rate at its current range of 4.25% to 4.5%. It is also keeping its outlook at two rate cuts for the remainder of this year, writes CNBC.
However, the Fed also announced that “uncertainty around the economic outlook has increased.”
Following the announcement, the broader market index rose 1.08%, blue-chip companies gained 0.92% and the NASDAQ Composite jumped 1.41%.
Despite political and economic uncertainty, some analysts remain bullish on AI’s growth. Insider trading draws attention in such times, as executives have unique company insights. For example, when a CEO or CFO buys stock, it may suggest confidence in the company’s future.
However, insider selling doesn’t always signal a lack of faith—it may be due to personal financial needs or asset diversification. Executives often use pre-set plans, like 10b5-1, to ensure transparency and avoid any perception of misconduct.
While insider trading can offer hints, it should be viewed alongside other factors like financial health, market trends, and industry shifts.
Our Methodology
Using Insider Monkey’s insider trading screener, we identified stocks with the highest insider purchase values in March.
Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
For each stock, we provide details on the total value of insider purchases this month and the company’s current market capitalization.
A scientist in a laboratory examining a test tube filled with a medication used to treat hypertension and cardiovascular diseases.
Mineralys Therapeutics, Inc. (NASDAQ:MLYS)
Total Value of Insider Purchases in March: $33.7 million
Market Capitalization: $1.05 billion
Mineralys Therapeutics is a clinical-stage biopharmaceutical company that develops medicines targeting diseases caused by dysregulated aldosterone. Its main product, lorundrostat, is in Phase 2 trials for hypertension and chronic kidney disease, with a pivotal program for resistant hypertension. The biotech is based in Radnor, Pennsylvania and is also one of the 10 Pump and Dump Stocks Favored by Hedge Funds.
Mineralys Therapeutics recently reported positive results from two key hypertension trials for lorundrostat. The Launch-HTN trial showed a significant systolic blood pressure reduction of 9.1 mmHg at week 6, sustained through week 12, while the Advance-HTN trial, conducted with the Cleveland Clinic, demonstrated a 7.9 mmHg reduction at week 12. Lorundrostat was well-tolerated in both trials, with minimal impact on potassium levels.
In March, three insiders bought a total of $33.7 million worth of Mineralys Therapeutics shares at a price of $13.50 per share. Since the beginning of the year, the stock rose 36.07% and currently trades at $16.75. Over the past 12 months, Mineralys Therapeutics shares returned 25.09% to its investors.
According to four analysts, Mineralys Therapeutics has an average rating of “Buy” with a 12-month price target of $27.00. The average price target represents an upside of 61.19% from its last price, writes MarketBeat.
Overall, MLYS ranks 3rd on our list of stocks that are receiving the most insider investment in March. While we acknowledge the potential of MLYS, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MLYS but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires
Disclosure: None. This article is originally published at Insider Monkey.
Hedge Fund Resource Center